Navigation Links
RBC Life Sciences' North American Nutritional Supplements and Medical Products Sales Increased, Year Over Year, During the First Quarter of 2009
Date:5/8/2009

IRVING, Texas, May 8 /PRNewswire-FirstCall/ -- (OTC Bulletin Board: RBCL) -- RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, reported today that its North American nutritional supplements and medical products sales grew, year over year, during the first quarter of 2009.

U.S. and Canadian sales of RBC Life Sciences' nutritional supplements and body care products increased to $1.49 million during the first quarter of 2009 compared to $1.47 million during the first quarter of 2008. The company's MPM Medical, Inc., brand saw its wound care and pain management products sales increase 10 percent to $1.50 million during the first quarter this year compared to $1.36 million during the same quarter of 2008.

RBC Life Sciences reported company-wide net sales of $6.02 million for the quarter ended March 31, 2009, compared to net sales of $6.35 million for the same quarter last year. The company also reported a net loss of $171,000, or $0.01 per share, during the first quarter of 2009 compared to net earnings of $355,000, or $0.02 per share, in 2008.

"One of our priorities late last year was to invest in the expansion of our domestic network marketing sales base," said RBC Life Sciences President and CEO, John W. Price. "We believe this investment is bearing fruit and will reward us moving forward, although our first quarter expenses exceeded the gross profit we generated from increased sales.

"Meanwhile, MPM Medical's pain management and wound care products are becoming increasingly popular within the medical field."

In addition to the investment to expand the North American sales base, first-quarter results were also affected by the delay in planned shipments to certain international licensees. As a result of some logistical factors, certain shipments scheduled for March 2009 were not shipped until April 2009.

Despite tough economic conditions, RBC Life Sciences has added approximately 2,000 new independent Associates since launching its domestic network marketing rebuilding effort in November 2008. The company soon will introduce a revised Associate compensation system that will be one of the industry's most-rewarding commission plans.

Mr. Price, who was promoted to CEO in January, began laying the framework in early 2008 for increased domestic and international growth across the company's nutritional supplements and medical products brands. In addition to hiring a sales director, communications director, science and technology director and a new vice president of marketing, Mr. Price recruited a strategic-growth veteran to the board of directors.

About RBC Life SciencesRBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange.


                             RBC Life Sciences, Inc.
                          Summary Results of Operations
                       (in thousands, except per share data)
                                 (unaudited)

                                                 Quarters Ended March 31,
                                                   2009          2008

     Net sales                                   $6,016        $6,348
     Gross profit                                 3,139         3,503
     Operating profit (loss)                       (161)          612
     Earnings (loss) before income taxes           (203)          567
     Provision (benefit) for income taxes           (32)          212
     Net earnings (loss)                           (171)          355

     Earnings (loss) per share - basic and
      diluted                                    $(0.01)        $0.02

     Weighted average shares outstanding -
       basic                                     21,917        21,114
     Weighted average shares outstanding -
      diluted                                    21,917        22,573



                             RBC Life Sciences, Inc.
                            Condensed Balance Sheets
                                 (in thousands)
                                  (unaudited)

                                                 March 31,   December 31,
                                                    2009         2008
     Assets
     Cash and cash equivalents                     $5,631       $4,973
     Inventories                                    5,202        5,707
     Other current assets                           2,467        2,245
       Total current assets                        13,300       12,925
     Other assets                                   7,031        6,841
       Total assets                               $20,331      $19,766

     Liabilities and shareholders' equity
     Accounts payable and accrued liabilities      $2,781       $3,228
     Deferred revenue                               5,450        4,279
     Other current liabilities                        147          144
       Total current liabilities                    8,378        7,651
     Other liabilities                              2,708        2,728
     Shareholders' equity                           9,245        9,387
       Total liabilities and shareholders'
        equity                                    $20,331      $19,766




'/>"/>
SOURCE RBC Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
2. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
4. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
5. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
6. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
7. Cardiac Science to Present at the UBS Global Life Sciences Conference
8. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
9. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
10. ViroPharma to Present at the UBS Global Life Sciences Conference
11. Clarient to Present at the UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... (PRWEB) , ... May 28, 2016 , ... May 26, ... Open Martial Arts Fighting Challenge with theme event of “K Warriors” on June 4, ... AL 36608. , The event is sponsored and hosted by Shaolin Institute and ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... caregivers to casual readers, this installment is bolstered by inspiring human-interest stories, courtesy ... trends and tech within the industry, from leading advocates, associations and industry leaders ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... scholarships to students studying complementary medicine. Allison Outerbridge is this year’s Life ... award on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... with discovery of thousands of defective respirators, according to court documents and SEC ... case of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 2016 LabStyle Innovations Corp . ... Tool, today announced that the Company,s Chief Financial Officer, ... being held June 1-2 in New York, NY ... 7-9 in Los Angeles, CA. ... and operational milestones, including the U.S. FDA Clearance and commercial ...
(Date:5/27/2016)... LONDON , May 27, 2016 ... an innovative biopharma company focused on the highly ... built a substantial pipeline of potential first-in-class or ... which are in development with strategic partners. HCM,s ... the fast-growing domestic market. We expect progress of ...
(Date:5/27/2016)... 27, 2016 Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that ... at two upcoming investor conferences: SeeThru Equity MicroCap ... New York City , NY When: ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, 109 ...
Breaking Medicine Technology: